These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 16220778)

  • 1. [Current status of HIV protease inhibitors].
    Yang QG; He XC; Bai DL
    Yao Xue Xue Bao; 2005 May; 40(5):389-94. PubMed ID: 16220778
    [No Abstract]   [Full Text] [Related]  

  • 2. Prodrugs of HIV protease inhibitors-saquinavir, indinavir and nelfinavir-derived from diglycerides or amino acids: synthesis, stability and anti-HIV activity.
    Gaucher B; Rouquayrol M; Roche D; Greiner J; Aubertin AM; Vierling P
    Org Biomol Chem; 2004 Feb; 2(3):345-57. PubMed ID: 14747863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, and evaluation of conformationally constrained tongs, new inhibitors of HIV-1 protease dimerization.
    Bouras A; Boggetto N; Benatalah Z; de Rosny E; Sicsic S; Reboud-Ravaux M
    J Med Chem; 1999 Mar; 42(6):957-62. PubMed ID: 10090778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereoisomers of cyclic urea HIV-1 protease inhibitors: synthesis and binding affinities.
    Kaltenbach RF; Nugiel DA; Lam PY; Klabe RM; Seitz SP
    J Med Chem; 1998 Dec; 41(25):5113-7. PubMed ID: 9836627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonsymmetrically substituted cyclic urea HIV protease inhibitors.
    Wilkerson WW; Dax S; Cheatham WW
    J Med Chem; 1997 Dec; 40(25):4079-88. PubMed ID: 9406598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of N-methylpiperazine for the preparation of piperazine-based unsymmetrical bis-ureas as anti-HIV agents.
    El-Faham A; Armand-Ugón M; Esté JA; Albericio F
    ChemMedChem; 2008 Jul; 3(7):1034-7. PubMed ID: 18383064
    [No Abstract]   [Full Text] [Related]  

  • 7. Stereocontrolled synthesis and biological activity of two diastereoisomers of the potent HIV-1 protease inhibitor saquinavir.
    Righi G; Ciambrone S; Bonini C; Campaner P
    Bioorg Med Chem; 2008 Jan; 16(2):902-8. PubMed ID: 17964171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclic HIV-1 protease inhibitors derived from mannitol: synthesis, inhibitory potencies, and computational predictions of binding affinities.
    Hultén J; Bonham NM; Nillroth U; Hansson T; Zuccarello G; Bouzide A; Aqvist J; Classon B; Danielson UH; Karlén A; Kvarnström I; Samuelsson B; Hallberg A
    J Med Chem; 1997 Mar; 40(6):885-97. PubMed ID: 9083477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and antiviral activity of P1' arylsulfonamide azacyclic urea HIV protease inhibitors.
    Huang PP; Randolph JT; Klein LL; Vasavanonda S; Dekhtyar T; Stoll VS; Kempf DJ
    Bioorg Med Chem Lett; 2004 Aug; 14(15):4075-8. PubMed ID: 15225729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptide inhibitors of HIV-1 and HIV-2 proteases: a comparative study.
    Pichová I; Weber J; Litera J; Konvalinka J; Vondrásek J; Soucek M; Strop P; Majer P; Heuser AM; Kraeusslich HG
    Leukemia; 1997 Apr; 11 Suppl 3():120-2. PubMed ID: 9209317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peptidomimetic inhibitors of HIV protease.
    Randolph JT; DeGoey DA
    Curr Top Med Chem; 2004; 4(10):1079-95. PubMed ID: 15193140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lysine sulfonamides as novel HIV-protease inhibitors: Nepsilon-acyl aromatic alpha-amino acids.
    Stranix BR; Lavallée JF; Sévigny G; Yelle J; Perron V; LeBerre N; Herbart D; Wu JJ
    Bioorg Med Chem Lett; 2006 Jul; 16(13):3459-62. PubMed ID: 16644213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV protease inhibitory bis-benzamide cyclic ureas: a quantitative structure-activity relationship analysis.
    Wilkerson WW; Akamike E; Cheatham WW; Hollis AY; Collins RD; DeLucca I; Lam PY; Ru Y
    J Med Chem; 1996 Oct; 39(21):4299-312. PubMed ID: 8863807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tricyclic ureas: a new class of HIV-1 protease inhibitors.
    Han W; Pelletier JC; Hodge CN
    Bioorg Med Chem Lett; 1998 Dec; 8(24):3615-20. PubMed ID: 9934481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel inhibitors of HIV protease: design, synthesis and biological evaluation of picomolar inhibitors containing cyclic P1/P2 scaffolds.
    Spaltenstein A; Almond MR; Bock WJ; Cleary DG; Furfine ES; Hazen RJ; Kazmierski WM; Salituro FG; Tung RD; Wright LL
    Bioorg Med Chem Lett; 2000 Jun; 10(11):1159-62. PubMed ID: 10866371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and evaluation of A-seco type triterpenoids for anti-HIV-1protease activity.
    Wei Y; Ma CM; Hattori M
    Eur J Med Chem; 2009 Oct; 44(10):4112-20. PubMed ID: 19493591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent inhibitors of the HIV-1 protease incorporating cyclic urea P1-P2 scaffold.
    Kazmierski WM; Furfine E; Gray-Nunez Y; Spaltenstein A; Wright L
    Bioorg Med Chem Lett; 2004 Nov; 14(22):5685-7. PubMed ID: 15482948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A three step continuous flow synthesis of the biaryl unit of the HIV protease inhibitor Atazanavir.
    Dalla-Vechia L; Reichart B; Glasnov T; Miranda LS; Kappe CO; de Souza RO
    Org Biomol Chem; 2013 Oct; 11(39):6806-13. PubMed ID: 24175328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and structure-activity study of shorter hexa peptide analogues as HIV-1 protease inhibitors.
    Narendra Babu SN; Rangappa KS
    Bioorg Med Chem; 2008 Jan; 16(2):874-80. PubMed ID: 17981043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-peptidic HIV protease inhibitors.
    Chrusciel RA; Strohbach JW
    Curr Top Med Chem; 2004; 4(10):1097-114. PubMed ID: 15193141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.